Verona Pharma to Present at Jefferies 2017 Global Healthcare Conference
LONDON, May 23, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (NASDAQ: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs, announced today that Jan-Anders Karlsson, PhD, CEO of Verona Pharma, is scheduled to present at the Jefferies 2017 Global Healthcare Conference.
An audio webcast of the presentation will be available on the Investors section of the company website, www.veronapharma.com. A replay of the webcast will be made available for 90 days following the presentation.
Event: Jefferies Healthcare ConferenceDate: June 8, 2017Time: 11:30 AM EDT Location: New York, NY
For further information, please contact:
| Verona Pharma plc | Tel: +44 (0)20 3283 4200 | |||||
| Jan-Anders Karlsson, Chief Executive Officer | [email protected] | |||||
| N+1 Singer (Nominated Adviser and UK Broker) | Tel: +44 (0)20 7496 3000 | |||||
| Aubrey Powell / James White | ||||||
| FTI Consulting (UK Media and Investor enquiries) | Tel: +44 (0)20 3727 1000 | |||||
| Simon Conway / Stephanie Cuthbert / Natalie Garland-Collins | [email protected] | |||||
| ICR, Inc. (US Media and Investor enquiries) | ||||||
| James Heins | Tel: +1 203-682-8251[email protected] | |||||
| Stephanie Carrington | Tel. +1 646-277-1282[email protected] |
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Labor Day Long Weekend Packing Secret: Vanessa Hudgens’ Go-To EKOUAER Satin Pajama Set for Effortless Travel Style
- Nebius Group announces pricing of upsized private offering of $5.0 billion of convertible senior notes
- JA Powers Fisher & Paykel Healthcare's Green Transition with New Zealand's Largest Rooftop PV System
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share